Psychedelics Archives - Page 9 of 17

Colorado finalizes business rules for psychedelics industry

The new rules include licensing procedures for mushroom growers and other business types and sets strict serving limits. The Colorado state government put the finishing touches...

Business11 months ago

Lykos to cut 75% of staff, reorganize in wake of FDA defeat

California-based Lykos Therapeutics announced a reorganization plan in the wake of the federal government’s rejection of its application for its MDMA-based drug designed to treat post-traumatic...

Bright Minds11 months ago

Bright Minds reports enough cash for coming year, but still no solid revenue stream

The company said it was seeking new sources of capital to support its research and development. New York-based biotech firm Bright Minds Biosciences Inc. (Nasdaq: DRUG)...

Business11 months ago

Seelos Therapeutics posts $1.7M net income, but warns it’s running out of cash

New York-based biotech firm Seelos Therapeutics Inc. (Nasdaq: SEEL) reported a net income of $1.7 million for the second quarter of the year, but the company...

Business11 months ago

Filament Health advances psilocybin drug, but is running low on cash

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) released its second-quarter financial results for the period ending June 30, 2024. Filament Health remains in a drug discovery phase...

Business11 months ago

Neuronetics to buy Greenbrook TMS in all stock deal

Neuronetics, Inc. (NASDAQ: STIM) is buying Greenbrook TMS Inc. (OTCMKTS: GBNHF) in an all-stock transaction. The combined company will continue to operate as Neuronetics, Inc., and...

Alto Neurosciences11 months ago

Alto Neurosciences reports enough cash to take it to 2027

Alto Neuroscience, Inc. (NYSE: ANRO) delivered its financial results for the second quarter ending June 30, 2024, and updated investors on its ALTO-100 drug. The company...

Business11 months ago

Enveric Biosciences narrows second-quarter loss, pushes non-hallucinogenic pipeline

The company aims to have a pre-Investigational New Drug meeting with the FDA for EB-003 in early 2025. Enveric Biosciences (NASDAQ: ENVB) reported a narrower second-quarter...

Business11 months ago

MindMed reassures investors with its cash cushion for drug studies

MineMed said it is on track for Phase 3 studies later this year. Mind Medicine Inc. (MindMed) Inc. (NASDAQ: MNMD) announced its financial results for the...

Atai Life Sciences11 months ago

Atai’s cash levels fall as company assures investors it has enough money

Atai Life Sciences (NASDAQ: ATAI) announced its second-quarter 2024 financial results and provided corporate updates. The company has little revenue to report as it is in...

MScannaBIZ.com

Colorado finalizes business rules for psychedelics industry

Lykos to cut 75% of staff, reorganize in wake of FDA defeat

Bright Minds reports enough cash for coming year, but still no solid revenue stream

Seelos Therapeutics posts $1.7M net income, but warns it’s running out of cash

Filament Health advances psilocybin drug, but is running low on cash

Neuronetics to buy Greenbrook TMS in all stock deal

Alto Neurosciences reports enough cash to take it to 2027

Enveric Biosciences narrows second-quarter loss, pushes non-hallucinogenic pipeline

MindMed reassures investors with its cash cushion for drug studies

Atai’s cash levels fall as company assures investors it has enough money

Judge dismisses lawsuit asking to block state's medical marijuana law

Celebrate the summer with a special promo offer from Al Capone

Nebraska Medical Marijuana Regulators Approve Emergency Rules Banning Flower Access For Patients

Alert: Department of Cannabis Control updates data dashboards with full data for 2023

Connecticut Appoints The US’s First Cannabis Ombudsperson – Yes there is a pun in there and I’m Sure Erin Kirk Is Going To Hear It More Than Once!

5 best CBD creams of 2024 by Leafly